查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860234

按產品類型、最終用戶、技術、分銷管道和應用分類的即時血脂檢測市場—2025-2032年全球預測

POC Lipid Testing Market by Product Type, End User, Technology, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，即時血脂檢測市場規模將達到 5.4932 億美元，複合年成長率為 6.44%。

關鍵市場統計數據
基準年 2024 3.3333億美元
預計年份：2025年 3.5486億美元
預測年份 2032 5.4932億美元
複合年成長率 (%) 6.44%

本文簡要概述了技術進步、臨床需求和監管政策的明確性如何重塑照護現場血脂檢測的交付模式。

照護現場血脂檢測已成為現代心血管代謝疾病預防保健的關鍵組成部分，能夠更快地進行風險評估並簡化臨床工作流程。檢測化學、設備小型化和介面設計的進步，共同降低了在傳統中心檢查室之外提供臨床實用血脂譜所需的時間和複雜性。因此，臨床醫生、照護團隊和患者現在都期望在就診時就能獲得更快、更具指導意義的三酸甘油酯和膽固醇值。

快速的技術創新、分散式醫療模式以及不斷變化的醫療保健系統獎勵，正在從根本上改變照護現場血脂檢測的普及和應用。

在技​​術創新和不斷發展的診療路徑的推動下，照護現場脂質診斷領域正經歷變革性的轉變。新型檢測法以及日益緊湊的桌上型和攜帶式分析儀縮小了與中心檢查室平台之間的性能差距，使得在照護現場更可靠的血脂檢查成為可能。這些技術進步輔以試劑穩定性的提升和工作流程的簡化，從而減輕了非檢查室人員的工作負擔。

本文分析了近期關稅如何重塑照護現場血脂診斷生態系統的供應鏈策略和採購方式。

美國近期實施的關稅政策為照護現場血脂檢測設備及耗材的生產商和供應商帶來了複雜的經營環境。部分進口診斷組件關稅的提高增加了依賴全球供應鏈的營業單位的成本，促使它們重新評估籌資策略和總到岸成本。因此，採購部門更加重視供應商多元化和合約保障，以維持利潤率並確保產品供應。

細分市場洞察揭示了產品類型、使用者環境、技術、通路和臨床應用如何共同決定產品採用趨勢。

產品細分洞察顯示，市場分為耗材和儀器兩大類。耗材包括品管、試劑盒和試劑等關鍵要素，這些要素決定了檢測性能和批間一致性。而儀器則包括適用於臨床和實驗室環境的桌上型分析儀，以及針對速度和便攜性進行最佳化的攜帶式分析儀。不斷變化的採購行為使消費者更加重視整體擁有成本和檢驗耗材的供應穩定性，因此，能夠確保試劑長期供應並提供簡單易用的儀器維護流程的製造商將獲得競爭優勢。

區域比較分析：闡釋不同法規結構、基礎設施成熟度和支付方環境對照護現場血脂檢測部署路徑的影響

區域趨勢將影響照護現場血脂檢測的推廣路徑和營運策略。在美洲，由於相對成熟的醫療保健體系和強大的商業分銷系統，臨床網路優先將快速診斷整合到基層醫療和社區診所中。這種環境促進了桌上型和攜帶式分析儀的普及，這些分析儀能夠提高工作流程效率並增強病人參與。此外，強大的診斷檢查室基礎也為混合部署模式提供了可能，在這種模式下，檢測方法會與中心檢查室的參考方法檢驗。

如何透過檢測方法創新、整合服務模式、策略夥伴關係以及嚴謹的臨床證據產生來建構競爭優勢

照護現場血脂檢測領域的競爭格局由產品創新、策略聯盟和臨床療效聲明三者共同驅動。主要企業正大力投資於檢測方法開發和使用者體驗工程，以透過準確性、速度和整合能力脫穎而出。隨著企業尋求確保原料供應並降低貿易政策波動風險，與試劑和組件供應商建立供應鏈聯盟和共同開發契約正變得越來越普遍。

為製造商和醫療系統領導者制定優先策略行動，以增強韌性、加速推廣應用並展現臨床和商業性價值。

產業領導者應優先考慮供應鏈多元化和生產彈性，以應對貿易政策波動和零件短缺的風險。投資建造區域組裝中心並尋找關鍵試劑和儀器組件的替代供應商，可以顯著降低關稅和物流波動帶來的風險。同時，他們也應評估能夠簡化組件複雜性的產品設計，從而實現靈活生產並根據需要快速更新法規。

我們採用嚴謹的混合調查方法，結合相關人員訪談、監管審查、設備基準化分析和專家檢驗，為策略決策提供支援。

本分析整合了一項混合方法研究的成果，該研究結合了對關鍵產業相關人員的定性訪談以及對監管、臨床和專利文獻的系統性回顧。研究透過與臨床實驗室主任、採購人員、醫療設備工程師和支付者進行結構化對話，檢驗了營運挑戰和實施標準，並將這些對話作為主要資訊來源。為了確保技術和臨床的嚴謹性，研究還參考了公開的監管文件、臨床試驗註冊資訊和同行評審的出版物，對這些觀點進行了三角驗證。

簡要概述強調了整合產品、臨床證據和供應鏈策略對於充分發揮照護現場血脂檢測潛力的迫切需求。

照護現場血脂檢測正處於轉折點，其發展動力源於技術進步、醫療分散化趨勢以及臨床醫生和患者期望的轉變。設備設計、耗材可靠性和分銷策略的相互作用將決定能否在各種臨床環境中有效推廣應用。同時，不斷變化的貿易政策和供應鏈現狀也要求企業建立更具韌性的商業模式和更切合實際的生產方案。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將基於人工智慧的分析技術整合到照護現場血脂檢測設備中，以實現心血管風險預測評估。
  • 在基層醫療機構中推廣使用攜帶式血脂檢測平台進行早期膽固醇管理
  • 開發一種結合血脂譜和生物標記的多重照護現場分析儀，用於全面的心血管風險分層
  • 監管核准對新興市場快速攜帶式血脂檢測系統商業化的影響
  • 診斷公司與遠端醫療服務提供者合作，為慢性疾病患者提供遠距血脂監測解決方案
  • 微流體晶片技術可減少照護現場血脂檢測的檢體用量並縮短檢測週期。
  • 照護現場設備製造商與健康保險公司進行策略合作，將血脂檢測納入預防保健方案。
  • 消費者對具備行動應用程式連接功能的家用側向層析血脂檢測套組的需求日益成長，這類試劑盒能夠與醫生即時共用數據。
  • 基於酵素的生物感測器的創新提高了照護現場血脂定量檢測的靈敏度和特異性。
  • 領先的診斷設備製造商針對資源有限的診所，制定了以經濟高效的方式推廣血脂檢測解決方案的打入市場策略。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的即時血脂檢測市場

  • 消耗品
    • 控制
    • 成套工具
    • 試劑
  • 裝置
    • 桌上型分析儀器
    • 手持式分析儀

9. 依最終用戶分類的即時血脂檢測市場

  • 診所
  • 診斷實驗室
  • 居家檢測
  • 醫院

10. 依技術分類的即時血脂檢測市場

  • 層析法
  • 比色法
  • 酵素法
  • 免疫檢測

11. 按分銷管道分類的即時血脂檢測市場

  • 診斷實驗室
  • 電子商務
  • 醫院藥房
  • 零售藥房

第12章：按應用分類的即時血脂檢測市場

  • 心血管疾病風險評估
  • 糖尿病管理
  • 預防性篩檢

13. 按地區分類的即時血脂檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按群體分類的即時血脂檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國即時血脂檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Roche Diagnostics International AG
    • Siemens Healthineers AG
    • Nova Biomedical Corporation
    • PTS Diagnostics, LLC
    • EKF Diagnostics Holdings plc
    • Trividia Health, Inc.
    • Chembio Diagnostics, Inc.
    • Arkray, Inc.
    • Meridian Bioscience, Inc.
Product Code: MRR-DD0700E81D15

The POC Lipid Testing Market is projected to grow by USD 549.32 million at a CAGR of 6.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 333.33 million
Estimated Year [2025] USD 354.86 million
Forecast Year [2032] USD 549.32 million
CAGR (%) 6.44%

A concise overview of how technological advances, clinical demand, and regulatory clarity are reshaping point-of-care lipid testing delivery models

Point-of-care lipid testing has emerged as a pivotal component in modern preventive cardiometabolic care, enabling more immediate risk assessment and streamlined clinical workflows. Advances in assay chemistry, device miniaturization, and interface design have collectively reduced the time and complexity required to deliver clinically actionable lipid profiles outside traditional central laboratories. As a result, clinicians, care teams, and patients now expect faster access to triglyceride and cholesterol metrics that can inform same-encounter decision-making.

Moreover, the convergence of remote monitoring, telehealth, and decentralized diagnostic strategies is reshaping how lipid testing is deployed in ambulatory settings, community clinics, and increasingly within the home. Regulatory authorities have clarified pathways for point-of-care devices while payers and health systems explore reimbursement and value pathways that reflect the potential for earlier intervention and reduced downstream costs. At the same time, laboratory professionals continue to emphasize the need for rigorous quality assurance, method comparability, and robust clinical validation to preserve diagnostic confidence.

Taken together, these dynamics create both opportunity and obligation for manufacturers, distributors, and healthcare providers. Industry players must balance speed-to-market with demonstrable accuracy, user-centric design, and integration capabilities that support electronic health record interoperability and clinical decision support. As adoption grows, stakeholders who proactively address operational, regulatory, and clinical alignment will be best positioned to capitalize on the shift toward more immediate lipid assessment.

How rapid innovation, decentralized care models, and evolving health system incentives are fundamentally altering point-of-care lipid testing adoption and delivery

The landscape for point-of-care lipid diagnostics is experiencing transformative shifts driven by technological innovation and evolving care pathways. New assay modalities and increasingly compact benchtop and handheld analyzers have narrowed the performance gap with central laboratory platforms, enabling more reliable lipid panels at the point of care. These technical gains are complemented by improved reagent stability and streamlined workflow designs that lower the operational burden on non-laboratory personnel.

Simultaneously, the rise of home testing and patient-centered care models has prompted device makers to focus on usability, connectivity, and data security. Vendors are investing in digital ecosystems that link test results to mobile apps and telehealth platforms, which supports shared decision-making between patients and clinicians. In parallel, clinical practice guidelines and payer policies are adapting to recognize the role of rapid lipid assessment in chronic disease management and preventive screening, which influences procurement priorities and deployment strategies.

Supply chain resilience has also become a strategic imperative, with manufacturers diversifying sourcing and considering regional production hubs to mitigate disruptions. As adoption broadens, partnership models are shifting away from one-size-fits-all sales toward outcome-oriented collaborations that offer bundled device-and-service solutions. Consequently, the market is moving toward a more integrated, patient-focused diagnostic paradigm where speed, quality, and interoperability determine long-term value.

An analytical review of how recent tariff measures have reshaped supply chain strategies and procurement approaches across the point-of-care lipid diagnostics ecosystem

Recent tariff measures implemented in the United States have created a complex environment for manufacturers and suppliers of point-of-care lipid testing equipment and consumables. Increased duties on certain imported diagnostic components have amplified costs for entities reliant on global supply chains, prompting organizations to re-evaluate sourcing strategies and total landed costs. As a direct result, procurement teams are placing greater emphasis on supplier diversification and contractual protections to preserve margin and maintain product availability.

In response, some vendors are accelerating discussions around nearshoring and local assembly to reduce exposure to cross-border tariff volatility. These shifts are not solely procurement-driven; they also influence product design choices as companies seek to reduce reliance on tariffed components by redesigning kits and instruments for regional manufacturing compatibility. At the same time, distributors and healthcare providers are responding by negotiating longer-term agreements and inventory buffers to smooth operational continuity.

Payment and contracting considerations are also adapting, since higher input costs can impact pricing structures and the relative attractiveness of bundled service offerings. Therefore, commercial teams and health system purchasers are increasing the sophistication of total cost assessments, taking into account logistics, regulatory compliance, and potential duties. Ultimately, tariff-related pressures are accelerating strategic shifts toward supply-chain resilience, regional manufacturing partnerships, and contract designs that hedge against future trade-policy changes.

Segment-specific insights revealing how product types, user settings, technologies, distribution pathways, and clinical applications jointly dictate adoption dynamics

Insight into product segmentation reveals that the market is bifurcated between consumables and instruments, with consumables encompassing essential elements such as controls, kits, and reagents that determine assay performance and lot-to-lot consistency, while instruments include both benchtop analyzers suited for clinic and laboratory environments and handheld analyzers optimized for speed and portability. Shifts in purchasing behavior often prioritize total cost of ownership and the availability of validated consumable supplies, so manufacturers that secure long-term reagent supply and deliver intuitive instrument maintenance protocols gain a competitive edge.

From an end-user perspective, adoption patterns vary across clinics, diagnostic laboratories, home testing settings, and hospitals. Clinical decision workflows in hospital and large outpatient settings tend to demand higher throughput and integration with existing laboratory information systems, whereas clinics and home testing emphasize ease of use, minimal sample handling, and rapid result turnaround to support point-of-care consultations. Diagnostic laboratories continue to act as quality hubs, often validating and benchmarking point-of-care outputs to ensure method concordance and to support clinician confidence.

Technology segmentation further highlights the diversity of approaches to lipid measurement. Chromatographic methods and immunoassays offer high analytical specificity and are frequently used in centralized contexts, while colorimetric and enzymatic methods provide simpler, faster pathways to lipid quantification at the point of care. Each technology presents trade-offs among accuracy, cost, and operational complexity; therefore, product positioning must align with the clinical setting and the skill level of intended users.

Distribution channels also shape accessibility and adoption. Diagnostic laboratories, e-commerce platforms, hospital pharmacies, and retail pharmacies each play distinct roles in getting devices and consumables into clinical and consumer hands. E-commerce accelerates direct-to-consumer access and simplifies repeat consumable purchases, whereas hospital and retail pharmacies enable integration into institutional procurement and patient support programs. Finally, application-driven demand-spanning cardiovascular risk assessment, diabetes management, and preventive screening-frames clinical utility and the types of outcome data purchasers require for reimbursement and guideline adoption. Manufacturers that tailor solutions to these application needs and distribution realities can better align product development and commercialization efforts with end-user expectations.

A regional comparative analysis explaining how differing regulatory frameworks, infrastructure maturity, and payer landscapes influence point-of-care lipid testing trajectories

Regional dynamics shape both the adoption trajectory and operational strategies for point-of-care lipid testing. In the Americas, clinical networks emphasize rapid diagnostics integration into primary care and community clinics, supported by relatively mature reimbursement frameworks and a strong private-sector distribution system. These conditions encourage adoption of both benchtop and handheld analyzers that can demonstrate workflow efficiencies and improved patient engagement. Additionally, a robust base of diagnostic labs provides opportunities for hybrid deployment models where point-of-care platforms are validated against central laboratory reference methods.

Across Europe, the Middle East, and Africa, regulatory and reimbursement environments are heterogeneous, driving a more localized approach to market entry. In parts of Europe, well-established health technology assessment mechanisms prioritize clinical validation and cost-effectiveness evidence, which favors devices that can demonstrate quality and outcome benefits. Meanwhile, in the Middle East and Africa, infrastructure gaps and variability in laboratory capacity create demand for portable, easy-to-use devices and consumables that can operate with limited facilities and supply chain constraints. Manufacturers should therefore align regulatory strategies and support models with local health system needs, leveraging partnerships with regional distributors and clinical networks.

Asia-Pacific presents a mix of high-volume urban centers with advanced diagnostic infrastructure and expansive rural areas where decentralized testing can deliver substantial public health value. A strong manufacturing base in several countries supports both regional production and export opportunities, while rapid digital adoption facilitates remote monitoring and integration with national health initiatives. In this region, payers and providers are increasingly receptive to innovations that reduce clinical bottlenecks and enhance chronic disease management, making Asia-Pacific an important locus for scalable deployment and iterative product refinement.

How competitive advantage is being forged through assay innovation, integrated service models, strategic partnerships, and rigorous clinical evidence generation

Competitive dynamics in the point-of-care lipid testing space are defined by a mix of product innovation, strategic partnerships, and claims to clinical validation. Leading organizations invest heavily in assay development and usability engineering to differentiate through accuracy, speed, and integration capabilities. Supply-chain partnerships and co-development agreements with reagent and component suppliers are increasingly common as firms seek to secure raw materials and mitigate risk from trade-policy shifts.

In addition to technical differentiation, commercialization strategies vary widely. Some firms focus on comprehensive service offerings that bundle devices with consumables, training, and remote quality oversight, while others pursue a more modular approach that emphasizes low-cost consumables and broad distribution through e-commerce and pharmacy channels. Strategic alliances with healthcare networks, telehealth providers, and electronic health record vendors are shaping interoperability and care pathway alignment, which in turn influence purchasing decisions among health systems and clinics.

Regulatory compliance and evidence generation remain central to competitive advantage. Companies that prioritize robust clinical evaluation and establish clear pathways for regulatory clearance and post-market surveillance build trust with clinical stakeholders. Moreover, firms that demonstrate responsiveness to payer expectations-by generating real-world evidence of clinical utility in cardiovascular risk assessment, diabetes management, and preventive screening-can materially strengthen their market positioning. Ultimately, success hinges on marrying credible science with scalable commercial models and resilient supply chains.

Prioritized strategic actions for manufacturers and health system leaders to strengthen resilience, accelerate adoption, and demonstrate clinical and commercial value

Industry leaders should prioritize supply-chain diversification and manufacturing flexibility to hedge against trade-policy disruptions and component shortages. Investing in regional assembly hubs and qualifying alternate suppliers for critical reagents and instrument parts can materially reduce exposure to tariff and logistics volatility. At the same time, organizations should evaluate product designs that simplify component complexity, enabling more adaptable production footprints and faster regulatory updates when needed.

Second, companies must accelerate user-centric design and connectivity features for both benchtop and handheld analyzers to drive adoption in decentralized settings and the home. Streamlined workflows, integrated quality controls, and secure data transfer to electronic health records will differentiate offerings and support clinician acceptance. Complementing these technical improvements with structured training programs and remote technical support will reduce user errors and enhance clinical confidence.

Third, manufacturers should deepen engagement with payers, professional societies, and health systems to generate the clinical evidence required for guideline inclusion and reimbursement. Collaborative pilot programs that measure impact on clinical decision-making and downstream outcomes will strengthen value propositions. Parallel commercial strategies should explore bundled service models that combine device placement, consumable supply, and performance monitoring to simplify procurement and improve adherence.

Finally, pursue partnerships that extend beyond traditional distribution-linking with telehealth platforms, chronic care management vendors, and pharmacy networks-to create integrated care pathways. These alliances can expand reach, support patient retention for longitudinal monitoring, and create differentiated offerings that capture greater downstream value.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, device benchmarking, and expert validation to support strategic decision-making

This analysis synthesizes insights derived from a mixed-methods research approach that combines primary qualitative interviews with key industry stakeholders and systematic review of regulatory, clinical, and patent literature. Primary inputs included structured conversations with clinical laboratory directors, procurement leaders, device engineers, and payers to validate operational pain points and adoption criteria. These perspectives were triangulated with publicly available regulatory filings, clinical trial registries, and peer-reviewed publications to ensure technical and clinical accuracy.

Quantitative elements of the methodology comprised device performance benchmarking and comparative assessments of assay principles, focusing on analytical sensitivity, specificity, and user workflow metrics. Supply-chain and trade-policy analyses were informed by customs and tariff schedules, logistics reports, and manufacturer disclosures to capture cost and availability implications. Throughout the process, findings were reviewed by an external panel of clinical and technical experts to stress-test assumptions and identify blind spots.

Limitations of the research include variability in regional data transparency and differences in clinical practice patterns that can influence adoption scenarios. To mitigate these constraints, the methodology emphasizes qualitative contextualization and cross-validation across multiple independent sources. The result is a pragmatic, evidence-focused assessment intended to support strategic decision-making rather than deterministic market projections.

A concise synthesis highlighting the imperative for integrated product, clinical evidence, and supply-chain strategies to realize point-of-care lipid testing potential

Point-of-care lipid testing stands at an inflection point, propelled by technological improvements, a shift toward decentralized care, and evolving expectations from clinicians and patients. The interplay between instrument design, consumable reliability, and distribution strategies will determine which solutions scale effectively across diverse clinical settings. Concurrently, trade-policy shifts and supply-chain realities necessitate more resilient commercial models and pragmatic manufacturing choices.

For stakeholders across the value chain, the imperative is clear: align product development with real-world clinical workflows, invest in evidence generation that addresses payer and guideline requirements, and construct flexible supply chains that support continuity of care. By doing so, organizations can unlock the clinical and operational benefits of rapid lipid assessment while safeguarding quality and accessibility. Ultimately, the most successful players will be those that integrate robust science, user-centric design, and adaptive commercial strategies to meet the needs of an increasingly decentralized diagnostic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-powered analysis in point-of-care lipid testing devices enabling predictive cardiovascular risk assessments
  • 5.2. Rising adoption of portable lipid testing platforms in primary care settings for early cholesterol management
  • 5.3. Development of multiplex point-of-care analyzers combining lipid profiles with biomarkers for comprehensive cardio risk stratification
  • 5.4. Impact of regulatory approvals on the commercialization of rapid handheld lipid testing systems in emerging markets
  • 5.5. Collaboration between diagnostics companies and telehealth providers to deliver remote lipid monitoring solutions for chronic patients
  • 5.6. Emergence of microfluidic chip technology to reduce sample volume and turnaround time in point-of-care lipid assays
  • 5.7. Strategic partnerships between point-of-care device manufacturers and health insurers to integrate lipid testing into preventive care packages
  • 5.8. Increasing demand for home-based lateral flow lipid testing kits integrated with mobile apps for real-time data sharing with physicians
  • 5.9. Innovation in enzyme-based biosensors for enhanced sensitivity and specificity in point-of-care lipid quantification
  • 5.10. Market entry strategies of major diagnostics firms focusing on cost-effective lipid testing solutions for resource-limited clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. POC Lipid Testing Market, by Product Type

  • 8.1. Consumables
    • 8.1.1. Controls
    • 8.1.2. Kits
    • 8.1.3. Reagents
  • 8.2. Instruments
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Handheld Analyzers

9. POC Lipid Testing Market, by End User

  • 9.1. Clinics
  • 9.2. Diagnostic Labs
  • 9.3. Home Testing
  • 9.4. Hospitals

10. POC Lipid Testing Market, by Technology

  • 10.1. Chromatographic Methods
  • 10.2. Colorimetric Methods
  • 10.3. Enzymatic Methods
  • 10.4. Immunoassays

11. POC Lipid Testing Market, by Distribution Channel

  • 11.1. Diagnostic Laboratories
  • 11.2. E-commerce
  • 11.3. Hospital Pharmacies
  • 11.4. Retail Pharmacies

12. POC Lipid Testing Market, by Application

  • 12.1. Cvd Risk Assessment
  • 12.2. Diabetes Management
  • 12.3. Preventive Screening

13. POC Lipid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. POC Lipid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. POC Lipid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Roche Diagnostics International AG
    • 16.3.3. Siemens Healthineers AG
    • 16.3.4. Nova Biomedical Corporation
    • 16.3.5. PTS Diagnostics, LLC
    • 16.3.6. EKF Diagnostics Holdings plc
    • 16.3.7. Trividia Health, Inc.
    • 16.3.8. Chembio Diagnostics, Inc.
    • 16.3.9. Arkray, Inc.
    • 16.3.10. Meridian Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. POC LIPID TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. POC LIPID TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. POC LIPID TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POC LIPID TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 304. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 305. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 306. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 307. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 336. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

TAB